GS 9131

Drug Profile

GS 9131

Alternative Names: GS 9148 phosphonoamidate prodrug; GS-9131

Latest Information Update: 18 Jul 2011

Price : $50

At a glance

  • Originator Gilead Sciences
  • Class Antiretrovirals; Purine nucleosides; Small molecules
  • Mechanism of Action Nucleoside reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Suspended HIV-1 infections

Most Recent Events

  • 26 Mar 2009 Preclinical pharmacokinetics data in HIV-1 infections presented at the 237th American Chemical Society National Meeting (237th-ACS-2009)
  • 17 Apr 2008 Preclinical toxicology data of GS 9148 in HIV-1 infections presented at the 21st International Conference on Antiviral Research (ICAR-2008)
  • 06 Feb 2008 Adverse events data from a preclinical trial presented at the 15th Conference on Retroviruses and Opportunistic Infections (CROI-2008)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top